Unknown NA INTERVENTIONAL 2-arm NCT05736042

Microinterventional Endocapsular Nuclear Fragmentation Assisted Cataract Surgery

Microinterventional Endocapsular Nuclear Fragmentation Assisted Cataract Surgery Versus Conventional Phacoemulsification Using Divide-and-conquer: a Randomized Controlled Trial

Sponsor: Carl Zeiss Meditec AG

Conditions Nuclear Cataract

Interventions Lens fragmentation

Updated 5 times since 2023 Last updated: Apr 6, 2023 Started: Apr 3, 2023 Primary completion: Jun 30, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Nuclear Cataract and is currently ongoing. Carl Zeiss Meditec AG leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
May 2023 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carl Zeiss Meditec AG
Oogziekenhuis Rotterdam
Stichting Wetenschappelijk Onderzoek Het Oogziekenhuis Prof.dr H.J. Flieringa

Data source: Oogziekenhuis Rotterdam

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rotterdam, Netherlands